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Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after
surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ
confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n = 86) or no adjuvant ADT (group 2, n = 86).
Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5–10-year clinical progression-free survival was 96.9%
(94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-
risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for
metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease
at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.
1. Introduction
Patients with high-risk localized prostate cancer (PCa) based
on either PSA >20 ng/mL, Gleason score (GS) ≥8, or an ad-
vanced clinical stage have a risk of biochemical failure of up
to 70% with surgery alone [1–5]. This has raised the
question on the need of adjuvant treatments including an-
drogen deprivation, radiation, and chemotherapy. Adjuvant
androgen deprivation therapy (ADT) has shown significant
improvement in disease-free survival for men with high-risk
PCa treated with definitive radiation therapy and a survival
benefit for men with GS 8–10 [6, 7]. For patients treated with
radical prostatectomy (RP) the role of adjuvant ADT is still
controversial. In a small prospective, randomized trial a sur-
vival benefit with adjuvant ADT in patients with lymph node
positive disease was shown [8]. Two retrospective studies
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have reported a survival advantage for immediate ADT in
patients with locally advanced disease [9, 10]. For patients
with pT3N0M0 PCa Thompson et al. recently reported
improved metastasis-free and overall survival (OS) with
adjuvant radiation therapy when compared to observation
[11]. Current guidelines therefore recommend adjuvant ra-
diation for these patients [12, 13]. However, the results of the
ADT-alone control arm of the SWOG study S9921 reported
on excellent 5-year progression-free (92.5%) and OS rates
(95.9%) for men with high-risk PCa treated with RP and
adjuvant ADT over a two-year period [14]. These excellent
results were seen despite a minority of patients receiving
adjuvant radiation and therefore suggest there might be a
role for adjuvant ADT in men with pT3 disease and/or posi-
tive surgical margin.
The aim of our study was to analyze the role of adjuvant
hormonal therapy in high-risk PCa patients with positive
section margins or non-organ confined disease, but without
nodal involvement, after radical prostatectomy in a matched
European multicenter study cohort.
2. Materials and Methods
2.1. Patient Population. The study included 1413 patients
with clinically localized high-risk PCa (PSA > 20 ng/mL,
cT3-4, biopsy GS 8–10) and negative bone scan who had
undergone RP at 7 tertiary referral centers between 1989 and
2005. Patients with positive section margins or non-organ
confined disease and negative lymph nodes represented the
study population. These patients were case matched in two
groups receiving either adjuvant ADT within the first 3
months after RP (group 1) or no adjuvant ADT (group 2)
(match criteria: age, clinical stage, biopsy and specimen Glea-
son score, pathological stage, and surgical margin status).
Hormone deprivation was continuous and varied according
to institutional preferences. Orchiectomy, LHRH-therapy,
or maximal androgen deprivation with flutamide were
performed. Neoadjuvant HT or adjuvant radiation therapy
was considered as exclusion criteria. All patients were staged
preoperatively with digital rectal examination (DRE), an
abdominopelvic computed tomography (CT) scan, and bone
scan. They underwent a wide radical prostatectomy with
pelvic lymph node dissection. Our study group is not ho-
mogenous for the extent of lymphadenectomy and varied
according to the institutional preferences, thus limiting
our study in this point. Salvage therapy such as androgen
deprivation (group 2 only) or radiotherapy was performed
in individual patients at biochemical or clinical recurrence.
2.2. Postoperative Evaluation and Endpoints. Follow-up in-
cluded a DRE and serum PSA analysis every 3 months for 2
years, every 6months until 5 years after surgery, and annually
thereafter. Imaging with US, CT scan, or bone scan was per-
formed at the appearance of biochemical progression (BP),
ormanifest symptoms. BPwas defined as PSA>0.2 ng/mL on
2 consecutive follow-up visits, clinical progression (CP) was
either defined as local recurrence (confirmed by histology
or imaging), or systemic recurrence (suspected by CT or
bone scan). Prostate cancer-specific mortality (PCSM) was
defined as the time from RP to death attributed to PCa
or disease-related complications. Prostate cancer-specific
survival (PCSS) was defined as the time from RP to PCSM.
Overall survival (OS) was defined as the time from RP to
death from any cause.
2.3. Statistical Analysis. Biochemical progression-free sur-
vival (BPFS), clinical progression-free survival (CPFS), over-
all survival (OS), and cancer-specific survival (PCSS) from
the time of surgery were defined as endpoints for this ret-
rospective analysis. Continuous variables were summarized
as the mean and standard deviation. The Kaplan-Meier
method was used to estimate the survivor function at various
time points. Group comparisons were made using the log-
rank test for survival endpoints. Univariate hazard ratios
and their 95% confidence intervals (CI) were estimated
using the Cox proportional hazards model. Prespecified
clinical variables considered in the Cox model included the
preoperative serum PSA, biopsy Gleason score, and clinical
stage. Pathological stage, specimen Gleason score, surgical
margin status, lymph node involvement, and adjuvant
ADT were used as postoperative parameters. A P value of
<0.05 was considered statistically significant. Cox regression
models were performed in order to identify subgroups of
patients who either benefit from adjuvant ADT or never
needed any ADT. Classification of subgroups was as follows:
Gleason score <7/7/>7; positive and negative section margin
pT2/T3/T4. Predefined endpoints were BP and CP. All
analyses were performed with R statistical software (R, free
software foundation). Multivariate analyses were insuﬃcient
to interpret since groups were too small.
3. Results
Out of 1413 patients 800 met the inclusion criteria. From
these 86 were matched into each group. The homogeneity of
both groups is shown in Table 1.
3.1. Biochemical Recurrence-Free Survival. At a median
follow-up of 67 months 35.5% of the patients developed BP.
BP was less frequent in group 1 when compared to group
2 (Table 2). The univariate Cox regression analyses are pre-
sented in Table 3.
3.2. Clinical Progression-Free Survival. Of the 86 patients in
group 1 only 5 (5.8%) experienced CP during follow-up.
On the contrary—although follow-up for clinical recurrence
was available only for 46 patients in group 2—CP was seen
in 12 of these 46 patients available for analysis (26.1%).
Estimated 5- and 10-year CPFS 96.9% and 94.3% for group
1 and 73.7% and 67.0% for group 2, respectively (P < 0.01)
(Table 2). None of the men with T2 tumors developed CP,
and the risk for T3a disease was fairly low (2/28 in group 1
versus 4/29 in group 2, P = 1.0). But all patients who de-
veloped CP had positive section margins. The risk was high-
est inmen with seminal vesical invasion (T3b) and univariate
cox regression analysis comparing both groups showed that
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Table 1: Preoperative and postoperative characteristics of the 172 matched patients.
Characteristic
Group 1 Group 2
Adjuvant ADT No adjuvant ADT
Patients number 86 86
Median age (years) 66.2 66.6
Median Follow-up (months) 69 66
Mean PSA, ng/mL (range) 31.5 (3–119) 28.4 (2.78–159)
Clinical stage, 1997 TNM, (number (%))
≤cT2 36 (41.8%) 48 (55.8%)
cT3 49 (57.0% ) 37 (43.0%)
cT4 1 (1.2 %) 1 (1.2%)
Biopsy Gleason score (number (%))
≤6 36 (41.8%) 44 (51.2%)
7 39 (45.3%) 32 (37.2%)
≥8 11 (12.9%) 10 (11.6%)
Pathol. stage, 1997 TNM (number (%))
pT2 4 (4.7%) 9 (10.5%)
pT3a 28 (32.5%) 29 (33.7%)
pT3b 50 (58.1%) 45 (52.3%)
pT4 4 (4.7%) 3 (3.5%)
Pathol. Gleason score (number (%))
≤6 34 (39.5%) 34 (39.5%)
7 39 (45.4%) 39 (45.4%)
≥8 13 (15.1%) 13 (15.1%)
Surgical margins (number (%))
Positive 62 (72.1%) 66 (76.7%)
Negative 24 (27.9%) 20 (23.3%)
Salvage therapy
ADT 0 (0.0%) 25 (29.1%)
Radiotherapy 3 (3.5%) 9 (10.5%)
PSA: prostate-specific antigen; ADT: androgen deprivation therapy.
Table 2: Freedom from biochemical progression free-survival (BPFS), clinical progression-free (CPFS), cancer-specific (CSS), and overall
survival (OS).
Projected survival
Group 1 ADT (n = 86) Group 2 no ADT (n = 86)
P value
5 years 10 years 5 years 10 years
BPFS 87.7% 76.3% 37.1% 30.6% <0.001
CPFS 96.9% 94.3% 73.7% 67.0% 0.003
CSS 100% 100% 100% 91.0% 0.9
OS 94.4% 83.8% 97.1% 76.4% 0.6
Table 3: Univariable cox regression models for comparing groups 1 and 2; endpoint: biochemical recurrence and clinical progression. (For
clinical progression follow-up data were available for 132 patients).
Biochemical progression Clinical progression
HR (95% CI) P value HR (95% CI) P value
Whole sample 0.15 (0.08–0.29) <0.001 0.21 (0.08–0.6) 0.003
Low Gleason <7 0.16 (0.08–0.31) <0.001 0.25 (0.08–0.8) 0.02
High Gleason ≥7 0.11 (0.01–0.86) 0.04 0.18 (0.02–1.6) n.s.
R0 0.13 (0.03–0.48) 0.002 1.15 (0.1–13.4) n.s.
R1 0.16 (0.75–0.32) <0.001 0.15 (0.04–0.53) <0.01
pT3a n.s. n.s. n.s. n.s.
pT3b 0.15 (0.08–0.29) <0.001 0.26 (0.09–0.75) 0.013
pT4 0.22 (0.02–2.1) n.s. n.s. n.s.
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tumor stage, surgical margin status, and Gleason score were
predictors for CP (Table 3). The numbers were too small for
multivariate cox regression analysis.
3.3. Cancer-Specific Survival and Overall Survival . Survival
for the entire cohort was excellent. There have been 20
deaths (11.6%) including only 4 PCa-related deaths (2.3%).
Although there was no statistically significant diﬀerence for
OS and PCSS between both groups none of the patients in
group 1 died PCa-related while 4 in group 2 died on their
prostate cancer. The estimated 10-year. OS and PCSS was
83.8% and 100% for group 1 and 76.4% and 91.0% for group
2, respectively (Table 2).
4. Discussion
There is increasing evidence that surgery provides a rea-
sonable treatment option for selected men with high-risk
prostate cancer [1, 5, 15, 16]. The recently reported results
of the control arm of the SWOG-study S9921 showed that
the combination of surgery and combined adjuvant ADT is
associated with favorable disease-free and overall survival of
greater than 92% at 5 years of follow-up [14]. Our study
results corroborate these better than expected survival rates
even for a high-risk cohort with positive section margins or
non-organ confined disease and negative lymph nodes (8-
year PCSS 97.5% and OS 92.7%). The results reported here
and in the S9921-trial together with the improved outcomes
for the combination of radiation and ADT in men with high-
risk prostate cancer support the use of a multimodal treat-
ment including adjuvant ADT [7, 8, 17]. However, the sur-
vival rates reported in these trials reach up to 90% for PCSS
and 76% for OS, indicating that what we currently define as
“high-risk” disease group indeed is a heterogeneous cohort
with better than expected outcomes. These limitations in risk
assessment are also visible in the adjuvant radiation therapy
(RT) trials. Although some diﬀerences exist among the inclu-
sion criteria, these studies showed a benefit for immediate
adjuvant radiation in terms of biochemical progression (haz-
ard ratio 0.47, 95% CI: 0.4–0.56, P < 0.0001) [17]. But only
the SWOG-study could show a significant improvement in
metastasis-free and OS of 1.8 and 1.9 years, respectively [11].
Overtreatment is obvious from these RT trials: the number
needed to treat was 12.2 to prevent metastasis in one patient
at 12.6 years of follow-up and the number needed to treat
was 9.1 to prevent one death at the same time. Therefore,
Colette et al. tried to substratify the patients from EORTC-
trial 22911 and identified men with positive section margins
to be at higher risk for biochemical progression (relative risk
reduction of 62% for irradiated men, HR 0.38) [18].
The excellent outcomes observed in men receiving adju-
vant ADT raise two questions. (1) Overtreatment; the results
of the control arm of the S9921-trial show better than ex-
pected survival rates with adjuvant ADT over a two-year
period [14]. These excellent results raise the question
whether adjuvant ADT was necessary in all patients after
surgery. ADT is related to a wide variety of metabolic and
cardiovascular eﬀects that impact morbidity and mortality
of PCa patients [19]. Treatment deescalation therefore is
an important step forward in treating men with PCa. Our
matched analysis showed that 43% of the patients treated
by RP alone never experienced BP during follow-up and the
estimated 10-year biochemical progression-free survival for
this groupwas 30.6%. However, PSA is limited as an outcome
parameter and not all patients with biochemical recurrence
will develop metastasis and finally die on their PCa thus
limiting this information in patients counseling [20, 21].
Analysis therefore should be focused on clinical progression
and survival. Although our data for group 2 are limited
in terms of clinical recurrence—follow-up information for
this outcome measure were available only for 46/86 men
in this group—the risk for CP was significantly lower for
group 1 when compared to group 2 (5.7% versus 26.1%).
Men with T2 and T3a tumors (irrespective to the surgical
margin status) had a very low risk of CP and PCSM and
therefore adjuvant ADT can be avoided in these patients.
(2) The excellent outcomes make compelling argument for
a better definition of high-risk patients for future trials. We
identified tumor stage, surgical margin status, and Gleason
score as predictors for CP. Men with T3b margin positive
disease are at increased risk for CP and benefit from adjuvant
ADT with a hazard ratio of 0.25 when comparing group 1
and 2. EAU guidelines state two options that can be oﬀered
to patients with pT3b tumors and positive margins: either an
immediate radiotherapy to the surgical bed, upon recovery
of urinary function, or monitoring followed by salvage
radiotherapy at PSA rising, not exceeding 0.5 ng/mL (level
of evidence 1 and 3) [12]. However, this trial was conducted
to assess the role of adjuvant ADT in high-risk PCa patients
after surgery. Since this study lacks a radiotherapy arm,
comparison to other adjuvant therapy regimens cannot be
drawn. Side eﬀects, costs, and benefits have to be considered
when deciding on adjuvant therapy. In our study survival
rates were excellent—only 11.6% of the patients died overall
and 2.3% tumor related. Although not statistically significant
some diﬀerences in the outcome between both treatment
groups have to be mentioned. None of the patients in group
1 died tumor related versus 4 in group 2. All of these 4
men had positive surgical margins and 3/4 T3b tumors, thus
suggesting that these patients might benefit from immediate
adjuvant ADT. In general, the risk of death is rather low
even for the group of T3b patients. Further subanalyses are
necessary to identify those men at highest risk for CP and
PCSM. It is important to mention that all patients in the
adjuvant ADT group received continuous ADT. It is therefore
not possible to address the question whether this approach
is superior to shorter-term adjuvant ADT or PSA-triggered
ADT. In a retrospective study Siddiqui et al. reported on the
outcome of a contemporary RP cohort of 6401 men and
compared the outcome of immediate-versus deferred PSA-
triggered ADT and found no diﬀerences in CSS [22].
We recognize that our study is not without limitations.
Its retrospective nature may have caused a selection bias
towards patients who, although considered high risk, were
still deemed suitable for surgery. Variations in the extent of
lymphadenectomy and in pathology review as well as the
use of salvage treatments might have influenced our results.
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The study design and the low number of events (clinical
recurrence, and PCSM) limit the power of the analysis.
Despite these limitations, the results of thismatchedmul-
ticenter study on RP and adjuvant ADT provide useful infor-
mation for clinical decision making for men with high-risk
prostate cancer and adverse histopathological parameters.
5. Conclusion
Our results indicate excellent outcomes for high-risk prostate
cancer with positive section margins or non-organ confined
disease but negative lymph nodes after surgery. Patients
with T2/T3a tumors are at low risk for metastatic disease
and cancer-related death even in case of positive section
margins—adjuvant ADT therefore can be avoided in these
patients. Pathological stage and section margin status allows
us to identify men with T3b surgical margin positive disease
at highest risk for clinical progression. These patients benefit
from immediate adjuvant ADT. However, such risk strati-
fication is limited and far away from personalized therapy.
Research energy should be focused on the identification
and validation of new molecular markers to identify lethal
disease. We recently described a new biomarker to predict
clinical recurrence in high-risk PCa patients [23].
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